|
|
Post by od on Sept 10, 2016 13:45:58 GMT -5
I get that most on this board have unique experience with Afrezza's market introduction, apart from MNKD's market valuation. Some have experience in pharmaceutical marketing, others in aligned businesses -- all have watched and been frustrated (and financially insulted) by obvious blocking and tackling errors. What I don't get is that even with the overwhelming support of Mike's 2.0 strategy, which includes staging DTC in a way that does not blindside prescribers and frustrate patients, there are immediate implementation DTC tactical suggestions almost daily. Sure, many excellent ideas, but the cognitive dissonance, for me anyway, is confusing.
|
|
|
|
Post by b2011wilder on Sept 10, 2016 19:28:26 GMT -5
What's dissonant and confusing to me is the low refill rate. I look at the Nrx and see that somewhere around 30,000 new scripts have been written since launch, but refills are running around 130-140 a week. What gives? I looked up numbers for Victoza and Januvia and even after their new script numbers leveled off and even declined, refills continued to rise.
|
|
|
|
Post by saxcmann on Sept 10, 2016 19:39:10 GMT -5
What's dissonant and confusing to me is the low refill rate. I look at the Nrx and see that somewhere around 30,000 new scripts have been written since launch, but refills are running around 130-140 a week. What gives? I looked up numbers for Victoza and Januvia and even after their new script numbers leveled off and even declined, refills continued to rise. Know one knew how to drive a Ferrari stuck in 2nd gear... |
|
|
|
Post by MnkdWASmyRtrmntPlan on Sept 10, 2016 21:57:59 GMT -5
What's dissonant and confusing to me is the low refill rate. I look at the Nrx and see that somewhere around 30,000 new scripts have been written since launch, but refills are running around 130-140 a week. What gives? I looked up numbers for Victoza and Januvia and even after their new script numbers leveled off and even declined, refills continued to rise. Remember, your 30,000 is from the time Sanofi started selling. Those sales have all been stopped and new sales are starting with Mannkind 2.0, which has just started availability. Also, the weekly refill numbers are just what got refilled that week. So, remember, some get their refills once per month, some once per 3 months. Sales are all new now. I don't know if this helped, but I hope it did. |
|
|
|
Post by op2778 on Sept 10, 2016 22:23:59 GMT -5
From Afrezza website: ✞This physician locator tool is provided by MannKind Corp. (“MannKind”) solely to assist you in locating a physician who has experience with AFREZZA. I read in some tread in this board that there are almost 1200 drs registered. Now, I'm wondering: If 20% of them (240 just for this exercise) make just 2 new prescription per week to patients out of control, why scripts are still so Low?
It's seems reasonable just 2 new prescription per week or I'm totally out of my mind?
Op
|
|
|
|
Post by nylefty on Sept 10, 2016 22:32:12 GMT -5
"What's dissonant and confusing to me is the low refill rate. I look at the Nrx and see that somewhere around 30,000 new scripts have been written since launch, but refills are running around 130-140 a week."
But there haven't been "around 30.000 new scripts." You were NOT looking at "the Nrx." There have been (more than) 30,000 TOTAL prescriptions (TRx). which include renewals and refills.
TRx = Total Prescriptions = Total prescriptions includes refills AND renewals
Read more: mnkd.proboards.com/thread/1742/afrezza-script-counts-symphony-data#ixzz4JukAfsi7 |
|
|
|
Post by xoxoxoxo on Sept 10, 2016 23:31:43 GMT -5
Bottom line is a huge number of people got scripts to try afrezza, and they didn't keep using it for reasons unknown. Either they couldn't get their insurance to keep paying for it, or they didn't like how it worked, etc.
Mnkd has to fix that which is why they're so focused on the support side once people get their scripts. Sanofi just pushed for the initial scripts and when people couldn't figure it out and quit using Afrezza the house came tumbling down.
If we can keep the users who try Afrezza coming back for more, we have a future. If we get the same refill rates Sanofi did, then it's game over.
|
|
|
|
Post by prvs on Sept 11, 2016 6:06:18 GMT -5
Nate of Nate's Notes pointed out that insurers are given incentives in the form of discounts by BP to provide coverage for a drug. He said that MNKD has to show the insurance companies that Afrezza will save them a boat load of money by preventing the complications that occur when the other "rapid acting" insulins are used. I think MNKD can start with ER visits and go from there. Unfortunately, because SNY never bothered to do the leg work MNKD has to start from square 1 to convince the insurance companies that Afrezza will save them money.
|
|
|
|
Post by b2011wilder on Sept 11, 2016 9:29:35 GMT -5
"What's dissonant and confusing to me is the low refill rate. I look at the Nrx and see that somewhere around 30,000 new scripts have been written since launch, but refills are running around 130-140 a week."
But there haven't been "around 30.000 new scripts." You were NOT looking at "the Nrx." There have been (more than) 30,000 TOTAL prescriptions (TRx). which include renewals and refills.
TRx = Total Prescriptions = Total prescriptions includes refills AND renewals
I just eyeballed the Nrx numbers listed on the symphony sheet provided here. Looking a little more closely, first 14 weeks was about 2500. Next 30 weeks averaged about 350 a week or 10,500. Next 40 weeks about 150 a week or 6,000. So closer to 20,000? But compare something like victoza, which reached 3,000 new scripts a week in seven weeks, but then flattened out, but the refills continued to rise steadily. Or januvia where scripts peaked at 15,000 a week at seven weeks but then started to decline to 11-12,000 a week, yet the refills continued to rise as well. It just seems that afrezza's refills should at least hold steady as the Nrx increases. |
|
|
|
Post by brotherm1 on Sept 11, 2016 10:13:06 GMT -5
" It just seems that afrezza's refills should at least hold steady as the Nrx increases."
Precisely bwildered. And hence the big reason the MNKD 2.0 game plan has been and is being implemented.
|
|
|
|
Post by rockstarrick on Sept 11, 2016 10:35:30 GMT -5
"What's dissonant and confusing to me is the low refill rate. I look at the Nrx and see that somewhere around 30,000 new scripts have been written since launch, but refills are running around 130-140 a week."
But there haven't been "around 30.000 new scripts." You were NOT looking at "the Nrx." There have been (more than) 30,000 TOTAL prescriptions (TRx). which include renewals and refills.
TRx = Total Prescriptions = Total prescriptions includes refills AND renewals
I just eyeballed the Nrx numbers listed on the symphony sheet provided here. Looking a little more closely, first 14 weeks was about 2500. Next 30 weeks averaged about 350 a week or 10,500. Next 40 weeks about 150 a week or 6,000. So closer to 20,000? But compare something like victoza, which reached 3,000 new scripts a week in seven weeks, but then flattened out, but the refills continued to rise steadily. Or januvia where scripts peaked at 15,000 a week at seven weeks but then started to decline to 11-12,000 a week, yet the refills continued to rise as well. It just seems that afrezza's refills should at least hold steady as the Nrx increases. It very well could take three months or longer, July is a tough time to re-launch Afrezza. If I was a PWD, the last thing I would want interrupting my summer would be a trip to the pharmacy every month. Most probably don't need a new rx yet IMO. |
|
|
|
Post by od on Sept 11, 2016 10:40:36 GMT -5
I just eyeballed the Nrx numbers listed on the symphony sheet provided here. Looking a little more closely, first 14 weeks was about 2500. Next 30 weeks averaged about 350 a week or 10,500. Next 40 weeks about 150 a week or 6,000. So closer to 20,000? But compare something like victoza, which reached 3,000 new scripts a week in seven weeks, but then flattened out, but the refills continued to rise steadily. Or januvia where scripts peaked at 15,000 a week at seven weeks but then started to decline to 11-12,000 a week, yet the refills continued to rise as well. It just seems that afrezza's refills should at least hold steady as the Nrx increases. It very well could take three months or longer, July is a tough time to re-launch Afrezza. If I was a PWD, the last thing I would want interrupting my summer would be a trip to the pharmacy every month. Most probably don't need a new rx yet IMO. Rick - I have no problem with Rx count at this point, but...I am quite sure most PWD are already visiting pharmacy on a regular basis. |
|
|
|
Post by rockstarrick on Sept 11, 2016 10:44:35 GMT -5
It very well could take three months or longer, July is a tough time to re-launch Afrezza. If I was a PWD, the last thing I would want interrupting my summer would be a trip to the pharmacy every month. Most probably don't need a new rx yet IMO. Rick - I have no problem with Rx count at this point, but...I am quite sure most PWD are already visiting pharmacy on a regular basis. My father in law (T1d) filled in June, no refill till September. He fills 4 times/year unless there is a problem, for example. |
|
|
|
Post by od on Sept 11, 2016 11:18:01 GMT -5
Rick - I have no problem with Rx count at this point, but...I am quite sure most PWD are already visiting pharmacy on a regular basis. My father in law (T1d) filled in June, no refill till September. He fills 4 times/year unless there is a problem, for example. I am totally on-board with not expecting refills to be a monthly event. |
|
|
|
Post by gamblerjag on Sept 11, 2016 12:31:45 GMT -5
off topic... I'm logged in but having trouble placing someone on ignore . I went to their name and then the icon but only said "send gift".. usually it has block member too.. is there sometimes a glitch ? thanks.
|
|
